Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Plasmablastic Lymphoma 1 Lymphomatoid Granulomatosis 1 Lymphoma, Primary Effusion 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1 Burkitt Lymphoma 1

Interventions

Temozolomide 101 Radiotherapy 50 Magnetic Resonance Spectroscopy 38 Radiation 28 Specimen Handling 25 pembrolizumab 23 Bevacizumab 23 Lomustine 16 Nivolumab 14 Surgical Procedures, Operative 11 atezolizumab 8 Cyclophosphamide 8 Biopsy 8 abemaciclib 7 Ipilimumab 7 Carboplatin 7 fludarabine 6 Radiotherapy, Intensity-Modulated 6 Aminolevulinic Acid 6 olaparib 5 Metformin 5 Drug Therapy 5 Diet, Ketogenic 5 Dianhydrogalactitol 5 regorafenib 4 poly ICLC 4 cemiplimab 4 Radiosurgery 4 Photons 4 Leukapheresis 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Glioblastoma × varlilumab × 1 year × Clear all

NCT03688178 2026-05-22

DERIVe

Duke University

Phase 2 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡